Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CHRNB4 | P30926 | 2/20 | 0.39 |
| ▸ | CHRNA3 | P32297 | 2/20 | 0.39 |
| ▸ | ERN1 | O75460 | 1/20 | 0.39 |
| ▸ | MAP4K1 | Q92918 | 1/20 | 0.37 |
| ▸ | MAPT | P10636 | 2/20 | 0.36 |
| ▸ | MEN1 | O00255 | 1/20 | 0.36 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.36 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.36 |
| ▸ | LOXL2 | Q9Y4K0 | 2/20 | 0.36 |
| ▸ | AXL | P30530 | 1/20 | 0.35 |
| ▸ | MERTK | Q12866 | 1/20 | 0.35 |
| ▸ | CCNT1 | O60563 | 1/20 | 0.35 |
| ▸ | CCNE2 | O96020 | 1/20 | 0.35 |
| ▸ | CCNE1 | P24864 | 1/20 | 0.35 |
| ▸ | CDK2 | P24941 | 1/20 | 0.35 |
| ▸ | CDK9 | P50750 | 1/20 | 0.35 |
| ▸ | ALK | Q9UM73 | 1/20 | 0.35 |
| ▸ | MET | P08581 | 1/20 | 0.35 |
| ▸ | HCAR2 | Q8TDS4 | 3/20 | 0.35 |
| ▸ | CLK1 | P49759 | 3/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1572958 | 0.88 | GSK3B (0.42) | CHRNB4CHRNA3ERN1MAP4K1MAPT | |
| SCHEMBL1572960 | 0.88 | GSK3B (0.42) | CHRNB4CHRNA3ERN1MAP4K1MAPT | |
| SCHEMBL1573943 | 0.88 | GSK3B (0.42) | CHRNB4CHRNA3ERN1MAP4K1MAPT | |
| SCHEMBL1571158 | 0.83 | MAP4K1 (0.43) | MAP4K1LOXL2AXLMERTKMET | |
| SCHEMBL1571371 | 0.80 | PTGS2 (0.45) | CHRNB4CHRNA3ERN1MAPTMEN1 | |
| SCHEMBL1877328 | 0.80 | ERN1 (0.38) | CHRNB4CHRNA3ERN1MAP4K1MAPT | |
| SCHEMBL1877330 | 0.80 | ERN1 (0.38) | CHRNB4CHRNA3ERN1MAP4K1MAPT | |
| SCHEMBL1571761 | 0.79 | PDK2 (0.47) | CHRNB4CHRNA3ERN1MAPTMEN1 | |
| SCHEMBL1571401 | 0.76 | MAPT (0.33) | CHRNB4CHRNA3MAPTSMN1; SMN2 | |
| SCHEMBL17795065 | 0.76 | LOXL2 (0.50) | ERN1MAP4K1MAPTMEN1KMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20100216767-A1 | QUINAZOLINES FOR PDK1 INHIBITION | AIKAWA MINA | 2010-08-26 | — | — | US | disclosed |
| US-20100121052-A1 | Novel compounds for treating proliferative diseases | JAIN RAMA | 2010-05-13 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100216767-A1 | QUINAZOLINES FOR PDK1 INHIBITION | PDK1, PDK2, PDK3 | CHRNB4 4428/4885CHRNA3 3910/4885ERN1 876/4885 |
| US-20100121052-A1 | Novel compounds for treating proliferative diseases | PDK1, PDK2, PDK3 | CHRNB4 4700/4885CHRNA3 4585/4885ERN1 984/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.